Table 1.
Clinical characteristics and CSF data of patients with NMOSD.
| Sex | Age | Duration from relapse | Laboratory data in CSF | Laboratory data in blood | Lesions in MRI analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total cell (lymphocyte) (1/µl) | Protein (mg/dl) | IgG index | OCB | Anti-AQP4 antibody | Other antibody | Spinal cord | Brain | Optic nerve | ||||
| NMO_1 | F | 47 | 3 months | 4 (4) | 64 | 0.43 | − | 75 < | – | C2–C5 | Multiple | − |
| NMO_2 | F | 71 | 3 months | 16 (14) | 46 | 0.49 | − | 75 < | – | C1–C6 | Multiple | − |
| NMO_3 | F | 30 | 4 days | 16 (14) | 59 | 0.65 | + | 75 < |
ANA Anti-SS-A |
Th1-8 | – | + |
| NMO_4 | F | 50 | 21 days | 33 (26) | 70 | Not measured | − | 75 < | – |
C1-3 C7-Th8 |
– | + |
| NMO_5 | F | 37 | 5 days | 18 (13) | 47 | Not measured | − | + |
Anti-SS-A Anti-SS-B |
C2-4 | A few | − |
| NMO_6 | F | 43 | 7 days | 1 (1) | 32 | 0.46 | − | + | Anti-SS-A | C3-Th6 | Brain stem | − |
| NMO_7 | F | 55 | 7 days | 9 (7) | 36 | 0.54 | − | 75 < | – | Th3 | A few | + |
| NMO_8 | F | 51 | 58 days | 1 (1) | 29 | 0.51 | Not measured | 5.5 | – | – | – | + |
| NMO_9 | F | 67 | 18 days | 20 (15) | 85 | 0.478 | − | + | – | C2-C6 | A few | − |
| NMO_10 | F | 41 | 30 days | 5 (5) | 38 | 0.56 | − | + | ANA | Th3-4 | – | − |
| NMO_12 | F | 55 | 15 days | 1 (1) | 35 | 0.41 | − | 15.3 | – | Th6-8 | Multiple | − |
| NMO_13 | F | 33 | 2 days | 4 (4) | 31 | 0.65 | + | 75 < |
ANA Anti-SS-A |
Th1-8 | – | + |
NMO neuromyelitis optica, CSF cerebrospinal fluid, lympho lymphocyte, OCB oligo clonal band, ANA anti-nuclear antibody.